Plasma Thrombin-Activatable Fibrinolytic Inhibitor (TAFI) among Healthy Subjects and Patients with Vascular Diseases: A Validation Study | Zendy

Jasone Monasterio | Zendy; Pedro Martínez Bermúdez | Zendy; D. Quiroga | Zendy; E. Francisco | Zendy; Beatriz Meneses | Zendy; Joan Montaner | Zendy

Open Access

Plasma Thrombin-Activatable Fibrinolytic Inhibitor (TAFI) among Healthy Subjects and Patients with Vascular Diseases: A Validation Study

Author(s) -

Jasone Monasterio,

Pedro Martínez Bermúdez,

D. Quiroga,

E. Francisco,

Beatriz Meneses,

Joan Montaner

Publication year - 2003

Publication title -

pathophysiology of haemostasis and thrombosis

Language(s) - English

Resource type - Journals

eISSN - 1424-8840

pISSN - 1424-8832

DOI - 10.1159/000083833

Subject(s) - fibrinolysis , medicine , stroke (engine) , monoclonal antibody , cardiology , antibody , immunology , mechanical engineering , engineering

Thrombin activable fibrinolysis inhibitor antigen levels (TAFI Ag ) exhibit a great inter-individual variability in healthy populations. Our aim is to determine whether variability is due to physiologic variations depending on genetic control or due to validation of the method,in order to allow a better interpretation of the results inpatients with vascular diseases. With this purpose, we performed a strategy validation of specific ELISA method, Zymutest TAFI Ag Hyphen Biomed, base don a commercial monoclonal antibody. After methodology validation we have recently determined plasma TAFI Ag levels in several groups of diseases such as septic patients, menopause and cerebrovascular diseases. TAFI was finally determined in acute ischemic stroke to know its relationship with stroke evolution and response to thrombolytic treatments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research